Home / 2020 / June / 24

Daily Archives: June 24, 2020

Wakaf Tapai water woes expected to be solved before Aidiladha celebration

— The water supply disruption at Wakaf Tapai area here, is expected to be resolved before Hari Raya Aidiladha on July 31, Syarikat Air Terengganu (SATU) chief executive officer Ir Atemin Sulong said.

 

He said only 10 per cent of the 200 houses were affected and the company would be doing some modifications to the water pump at a cost of RM120,000, for the benefit of the affected residents.

 

“The water disruption is due to unplanned housing development on hilly grounds, resulting in difficulties in the construction of pipelines for water to be channeled to certain areas,” he told reporters after a meeting with Wakaf Tapai residents here today.

 

 

 

Earlier, residents of Tanah Lot Skim Penempatan Kemudahan Awam (SPKA) in Wakaf Tapai, urged several parties to come forward to resolve the water issues they had been facing with since 2007, after no action was taken despite various complaints.

 

Atemin said to solve the water supply problem in Marang, SATU had requested for a RM500 million allocation from the state government because the water supply to the area had been from the Kuala Terengganu water treatment plant located about 50km from the district.

 

On the problem of water supply expected to occur in some areas of the state during the upcoming Aidiladha celebration, Atemin said water tankers would be on standby to supply clean water and should there be any water disruption, residents would be notified two weeks ahead.

 

 

 

Source: BERNAMA News Agency

Two suspects remanded over murder of elderly man in Ampang

Police have placed a 56-year-old contractor and his 35-year-old son under a seven-day remand starting today,  suspected of being involved with the murder of a senior citizen whose body was found at Jalan UP 3/1 Ukay Perdana, Ampang.

 

Ampang Jaya deputy police chief Supt Mohd Azam Ismail has confirmed the matter when contacted by Bernama.

 

He said the remand application was submitted to the Ampang Court under Section 302 for murder.

 

 

 

“The cause of death has yet to be determined and the autopsy is still underway,” he told Bernama today.

 

Yesterday, an elderly man who was found dead with half his body covered by earth, was suspected to have been killed near a rain retention pond of the Drainage and Irrigation Department at Jalan UP 3/1 Ukay Perdana.

 

Mohd Azam said following the discovery of the body at 1.30 pm, police arrested the contractor and his son who was working as a an excavator operator to assist in the investigation.

 

 

 

Source: BERNAMA News Agency

 

Recovered COVID-19 patients may have lower level of immunity – Health Ministry

The Health Ministry has found that recovered COVID-19 patients may have a lower level of immunity, besides the complications affecting their lungs and heart.

 

Health director-general Datuk Dr Noor Hisham Abdullah said it was found that the level of antibodies IgM (immunoglobulin M) and IgG (immunoglobulin G) would decrease after three months.

 

“So it may have an effect on the individual’s immunity. If the person has low immunity, the individual  can be susceptible to other infections not only COVID-19,” he said in his daily press conference here, today.

 

 

 

He was responding to an international report that said the lives of patients who have recovered from COVID-19 may not return to normal because some of them need lung transplants and also were at risk of getting heart attacks.

 

Dr Noor Hisham said the ministry should ensure follow-up care to monitor the health of COVID-19 patients who have recovered particularly in categories 4 and 5.

 

Category 4 patients are those who need oxygen, and category 5 patients are those who require ventilators to continue breathing.

 

 

The Health Ministry is currently monitoring patients who have recovered, to see the long-term side effects.

 

Dr Noor Hisham said the COVID-19 virus attacks the lungs and the impact of the ‘cytokine storm’  causes the virus to affect the blood vessels.

 

“Sometimes the blood flow slows down and blood clotting occurs. There are two or three patients we have seen this happen to in the intestines and kidneys,” he said,

 

Dr Noor Hisham said the current treatment for pneumonia was with Dexamethasone, while the ‘low-molecular-weight heparin’ medication was used to prevent blood clotting.

 

He said patients on ventilators when having lung inflammation can possibly suffer lung damage.

 

Dr Noor Hisham said the Health Ministry was also conducting tests at the Institute of Respiratory Medicine to look at the long-term studies of patients who had been on ventilators.

 

 

 

Source: BERNAMA News Agency

 

ADX Labs donates $100,000 to advance COVID-19 vaccine research

Steven M. Renner and Dawn O’Connell videoconference

Steven M. Renner of ADX and Dawn O’Connell of CEPI discuss the funding of COVID-19 vaccine research on a videoconference call on June 24, 2020.

The Coalition for Epidemic Preparedness Innovations (CEPI) is accelerating the development of candidate vaccines against COVID-19 with the financial support of Minneapolis-based technology company ADX Labs, Inc.

MINNEAPOLIS, June 24, 2020 (GLOBE NEWSWIRE) — ADX Labs, Inc. has donated $100,000 to the Coalition for Epidemic Preparedness Innovations (CEPI) to speed the development of COVID-19 vaccines. The donation was made by ADX Labs’ charitable arm, the ADX Foundation.

CEPI, which the journal Nature called “by far the largest vaccine development initiative ever against viruses that are potential epidemic threats,”has moved quickly to respond to the COVID-19 pandemic. To date, CEPI has funded a diverse portfolio of nine vaccine candidates against COVID-19, with the ambition of developing a safe, effective and globally accessible vaccine within a 12-18-month timeframe. To increase their chances of success, CEPI has also recently opened a new funding opportunity focusing on additional vaccine candidates that have the potential to be developed rapidly and manufactured globally at scale.

Steven M. Renner, founder and CEO of ADX Labs and chairman of the ADX Foundation said, “ADX is committed to making a difference throughout the world through the power of technology. In CEPI we have found a like-minded organization built on innovation and dedicated to preparedness. CEPI’s new Call for Proposals to accelerate vaccine candidates against COVID-19 is a highly promising initiative, and ADX Labs is proud to help CEPI’s vaccine development partners increase their chances of success.”

CEPI’s nine candidate vaccines against COVID-19

This composite image shows research and development of the nine vaccines against COVID-19 that CEPI has funded to date (from upper left hand corner: Clover Pharmaceuticals, CureVac, INOVIO, Moderna, Novavax, Themis, University of Hong Kong, University of Oxford, University of Queensland.)

Dr. Richard Hatchett, CEO of CEPI, said, “We are incredibly grateful for ADX Labs’ donation to expedite our work to develop an effective vaccine against COVID-19. This global pandemic has resulted in a devastating loss of lives, while also fracturing societies and shutting down economies. Investment in vaccines and other scientific innovations now is crucial to give us the best possible chance of ending this pandemic. We are therefore delighted to welcome ADX to the coalition.”

Mr. Renner concluded, “ADX Labs has a proven track record of backing technologies that improve people’s lives across the world. Since 2013 our ADX Foundation has invested in children and communities, and social justice. Today, supporting CEPI’s search for a COVID-19 vaccine and manufacturing an effective vaccine at scale is the best way that we can help.”

Media enquiries: Simon Cousins, scousins@adxnet.com 

About ADX Labs, Inc.

ADX Labs, Inc. (ADX) is a technology company focused on providing a range of innovative products and services for individuals, home-based businesses, and the small to medium enterprise market. ADX independently funds the ADX Foundation, a registered non-profit philanthropic organization which has invested in children, communities, and social justice since 2013. Learn more at http://adxlabs.com

About Coalition for Epidemic Preparedness Innovations (CEPI)

CEPI is an innovative partnership between public, private, philanthropic, and civil organizations to develop vaccines to stop future epidemics. Before COVID-19, CEPI’s priority diseases included Ebola, Lassa, Middle East Respiratory Syndrome, Nipah, Rift Valley Fever, Chikungunya and unknown pathogens (Disease X). Learn more at http://cepi.net

Two photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/dcf82aac-fa4a-442e-92ff-e146db9c720f
https://www.globenewswire.com/NewsRoom/AttachmentNg/caa9fa59-9c9e-4688-96d8-80fbab5cbc95

Novavax to Participate in H.C. Wainwright Fireside Chat Series

GAITHERSBURG, Md., June 24, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that John J. Trizzino, Senior Vice President, Chief Business Officer and Chief Financial Officer, will participate in the H.C. Wainwright Virtual Fireside Chat Series on Thursday, June 25. A topic of discussion will be Novavax’ COVID-19 vaccine candidate, NVX-CoV2373.

Fireside chat details are as follows:

Date: June 25, 2020
Time: 10:00 a.m. U.S. Eastern Time (ET)
Webcast: www.novavax.com, “Investors”/ “Events”, until September 25, 2020

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax recently initiated development of NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinical trial results expected in July of 2020. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Contacts:
Investors
Silvia Taylor and Erika Trahan
ir@novavax.com
240-268-2022

Media
Brandzone/KOGS Communication
Edna Kaplan
kaplan@kogspr.com
617-974-8659

ADX Labs donates $100,000 to advance COVID-19 vaccine research

Steven M. Renner and Dawn O’Connell videoconference

Steven M. Renner of ADX and Dawn O’Connell of CEPI discuss the funding of COVID-19 vaccine research on a videoconference call on June 24, 2020.

The Coalition for Epidemic Preparedness Innovations (CEPI) is accelerating the development of candidate vaccines against COVID-19 with the financial support of Minneapolis-based technology company ADX Labs, Inc.

MINNEAPOLIS, June 24, 2020 (GLOBE NEWSWIRE) — ADX Labs, Inc. has donated $100,000 to the Coalition for Epidemic Preparedness Innovations (CEPI) to speed the development of COVID-19 vaccines. The donation was made by ADX Labs’ charitable arm, the ADX Foundation.

CEPI, which the journal Nature called “by far the largest vaccine development initiative ever against viruses that are potential epidemic threats,”has moved quickly to respond to the COVID-19 pandemic. To date, CEPI has funded a diverse portfolio of nine vaccine candidates against COVID-19, with the ambition of developing a safe, effective and globally accessible vaccine within a 12-18-month timeframe. To increase their chances of success, CEPI has also recently opened a new funding opportunity focusing on additional vaccine candidates that have the potential to be developed rapidly and manufactured globally at scale.

Steven M. Renner, founder and CEO of ADX Labs and chairman of the ADX Foundation said, “ADX is committed to making a difference throughout the world through the power of technology. In CEPI we have found a like-minded organization built on innovation and dedicated to preparedness. CEPI’s new Call for Proposals to accelerate vaccine candidates against COVID-19 is a highly promising initiative, and ADX Labs is proud to help CEPI’s vaccine development partners increase their chances of success.”

CEPI’s nine candidate vaccines against COVID-19

This composite image shows research and development of the nine vaccines against COVID-19 that CEPI has funded to date (from upper left hand corner: Clover Pharmaceuticals, CureVac, INOVIO, Moderna, Novavax, Themis, University of Hong Kong, University of Oxford, University of Queensland.)

Dr. Richard Hatchett, CEO of CEPI, said, “We are incredibly grateful for ADX Labs’ donation to expedite our work to develop an effective vaccine against COVID-19. This global pandemic has resulted in a devastating loss of lives, while also fracturing societies and shutting down economies. Investment in vaccines and other scientific innovations now is crucial to give us the best possible chance of ending this pandemic. We are therefore delighted to welcome ADX to the coalition.”

Mr. Renner concluded, “ADX Labs has a proven track record of backing technologies that improve people’s lives across the world. Since 2013 our ADX Foundation has invested in children and communities, and social justice. Today, supporting CEPI’s search for a COVID-19 vaccine and manufacturing an effective vaccine at scale is the best way that we can help.”

Media enquiries: Simon Cousins, scousins@adxnet.com 

About ADX Labs, Inc.

ADX Labs, Inc. (ADX) is a technology company focused on providing a range of innovative products and services for individuals, home-based businesses, and the small to medium enterprise market. ADX independently funds the ADX Foundation, a registered non-profit philanthropic organization which has invested in children, communities, and social justice since 2013. Learn more at http://adxlabs.com

About Coalition for Epidemic Preparedness Innovations (CEPI)

CEPI is an innovative partnership between public, private, philanthropic, and civil organizations to develop vaccines to stop future epidemics. Before COVID-19, CEPI’s priority diseases included Ebola, Lassa, Middle East Respiratory Syndrome, Nipah, Rift Valley Fever, Chikungunya and unknown pathogens (Disease X). Learn more at http://cepi.net

Two photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/dcf82aac-fa4a-442e-92ff-e146db9c720f
https://www.globenewswire.com/NewsRoom/AttachmentNg/caa9fa59-9c9e-4688-96d8-80fbab5cbc95

Novavax to Participate in H.C. Wainwright Fireside Chat Series

GAITHERSBURG, Md., June 24, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that John J. Trizzino, Senior Vice President, Chief Business Officer and Chief Financial Officer, will participate in the H.C. Wainwright Virtual Fireside Chat Series on Thursday, June 25. A topic of discussion will be Novavax’ COVID-19 vaccine candidate, NVX-CoV2373.

Fireside chat details are as follows:

Date: June 25, 2020
Time: 10:00 a.m. U.S. Eastern Time (ET)
Webcast: www.novavax.com, “Investors”/ “Events”, until September 25, 2020

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax recently initiated development of NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinical trial results expected in July of 2020. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Contacts:
Investors
Silvia Taylor and Erika Trahan
ir@novavax.com
240-268-2022

Media
Brandzone/KOGS Communication
Edna Kaplan
kaplan@kogspr.com
617-974-8659